Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial

Parkinsonism and Related Disorders

Volumn 18, Issue 4, 2012, Pages 370-376

  Rascol, O ^a   Bronzova, J ^b   Hauser, R A ^c   Lang, A E ^d   Sampaio, C ^e   Theeuwes, A ^b   van de Witte, S V ^b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Chemical Design and Synthesis Unit   (Netherlands)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e HOSPITAL DE SANTA MARIA   (Portugal)

Author keywords

Dyskinesia; Motor fluctuations; Pardoprunox (SLV308); Parkinson's disease; Partial dopamine agonist

Indexed keywords

LEVODOPA; PARDOPRUNOX; PLACEBO;

ADJUVANT THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NAUSEA; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL ANALOG SCALE;

ADULT; AGED; ANTIPARKINSON AGENTS; BENZOXAZOLES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PAIN MEASUREMENT; PARKINSON DISEASE; PIPERAZINES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860377625     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.12.006     Document Type: Article

References (28)

1. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999, 22:123-144.
2. Rascol O., Payoux P., Ory F., Ferreira J., Brefel-Courbon C., Montastruc J.L. Limitations of current Parkinson's disease therapy. Ann Neurol 2003, 53(Suppl. 3):S3-S15.
3. Lieberman A., Olanow C.W., Sethi K., Swanson P., Waters C.H., Fahn S., et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 1998, 51:1057-1062.
4. Rascol O., Brooks D., Melamed E., Oertel W., Poewe W., Stocchi F., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomized, double-blind, parallel-group trial. Lancet 2005, 365:947-954.
5. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease treatment guidelines. Neurology 2001, 56(Suppl 5):S1-S88.
6. Lape R., Colquhoun D., Sivilotti L.G. On the nature of partial agonism in the nicotinic receptor superfamily. Nature 2008, 454:722-727.
7. McCreary A.C., Ronken E., van der Heyden J., et al. SLV308: a novel antiparkinsonian agent with antidepressant and anxiolytic properties. Parkinson's disease (solvay pharmaceutical conferences) 2002, 51-58. IOS Press, USA. E. Ronken, G.J.M. van Scharrenburg (Eds.).
8. Tayarani-Binazir K., Jackson M.J., Rose S., McCreary A.C., Jenner P. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesias in MPTP treated common marmosets. Exp Neurol 2010, 226(2):320-327.
9. Johnston L.C., Jackson M.J., Rose S., McCreary A.C., Jenner P. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. Mov Disord 2010 Oct 15, 25(13):2059-2066.
10. Bronzova J., Sampaio C., Hauser R.A., Lang A.E., Rascol O., Theeuwes A., et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 2010, 62(1):40-48.
11. Hauser R.A., Bronzova J., Sampaio C., Lang A.E., Rascol O., Theeuwes A., et al. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. Eur Neurol 2009, 62(1):40-48.
12. Sampaio C., Bronzova J., Hauser R.A., Lang A.E., Rascol O., van de Witte S.V., et al. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. Mov Disord 2011, 26(8):1464-1476. for the Rembrandt/Vermeer Study Groups.
13. Daniel S.E., Lees A.J. Parkinson's disease society brain bank, London: overview and research. J Neural Transm Suppl 1993, 39:165-172.
14. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1967, 17(5):427-442.
15. Peto V., Jenkinson C., Fitzpatrick R., Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995, 4(3):241-248.
16. Clarke C.E., Speller J.M., Clarke J.A. Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000, (2):CD002261. 10.1002/14651858.CD002261.
17. Lieberman A., Ranhosky A., Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997, 49:162-168.
18. Hauser R.A., Hubble J.P., Truong D.D. Istradefylline US-001 Study Group. randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD. Neurology 2003, 61(3):297-303.
19. Zigmond A.S., Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370.
20. Nègre-Pagès L., Grandjean H., Lapeyre-Mestre M., Montastruc J.L., Fourrier A., Lépine J.P., et al. Anxious and depressive symptoms in Parkinson's disease: the French cross-sectionnal DoPaMiP study. Mov Disord 2010 Jan 30, 25(2):157-166. DoPaMiP Study Group.
21. Collins S.L., Moore R.A., McQuay H.J. The visual analogue pain intensity scale: what is moderate pain in millimetres?. PAIN 1997, 72:95-97.
22. LeWitt P.A., Lyons K.E., Pahwa R., SP 650 Study Group Advanced Parkinson disease treated with rotigotine transdermal system. PREFER study. Neurology 2007, 68:1262-1267.
23. Rascol O., Poewe W., Lees A., Aristin M., Salin L., Juhel N., et al. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson's disease and motor fluctuations. The ADVANS Study. Arch Neurol 2008, 65(5):577-583.
24. Parkinson Study Group A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. the PRESTO study. Arch Neurol 2005, 62:241-248.
25. Clarke C.E., Deane K. Ropinirole for levodopa-induced complications in Parkinson's disease (Review). Cochrane Database Syst Rev 2001, (1):CD001516. 10.1002/14651858.CD001516.
26. Barone P., Poewe W., Albrecht S., Debieuvre C., Massey D., Rascol O., et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9(6):573-580.
27. Nègre-Pagès L., Regragui W., Bouhassira D., Grandjean H., Rascol O., DoPaMiP Study Group Chronic pain in Parkinson's disease: the cross-sectional French DoPaMiP survey. Mov Disord 2008, 23(10):1361-1369.
28. Farrar J.T., Portenoy R.K., Berlin J.A., Kinman J.L., Strom B.L. Defining the clinically important difference in pain outcome measures. Pain 2000, 88(3):287-294.